Summary
- Pfizer obtained FDA approval for drugs Vyndaqel and Vyndamax to treat patients with transthyretin amyloid cardiomyopathy.
- Vyndaqel and Vyndamax are the first drugs approved to treat ATTR-CM specifically, with potential competition in the future stemming from Alnylam and possibly Ionis with partner Akcea.
- Analysts estimate that Pfizer's drugs for ATTR-CM could generate as much as $2 billion in peak sales so long as a strong marketing plan and patient education are implemented successfully.
- Approval of tafamidis was given by the FDA on the basis of a positive phase 3 study, in which the drug proved to be stat sig over placebo in both all-cause mortality and frequency of cardiovascular-related hospitalizations compared to placebo.
- Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our model portfolio. Start your free trial today ยป
Pfizer (PFE) was able to obtain FDA approval for its drugs by the name of Vyndaqel and Vyndamax (tafamidis) to treat patients with transthyretin amyloid cardiomyopathy. This is a good approval for the company because it has given itself a great opportunity to target a space with no competition for a few years. However, there are several competitors that have already received approval for a disease closely similar to ATTR-CM. This remains as a major risk to potential sales for both Vyndaqel and Vyndamax.
